Ausgabe 3/2014
Inhalt (12 Artikel)
2013 ACC/AHA Guideline: A Guideline for the Population—Without Evidence from the Population
Merle Myerson, Robert S. Rosenson
The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?
Manfredi Rizzo, Dimitri P. Mikhailidis, Khalid Al-Rasadi
Healthy Aging in Finland: Patients Adhere Well to Chronic Statin Therapy and Their Doctors to the Guidelines
Robert H. Vander Stichele, Yoleen Van Camp
Granulocyte-Colony Stimulating Factor Reduces Cardiomyocyte Apoptosis and Ameliorates Diastolic Dysfunction in Otsuka Long-Evans Tokushima Fatty Rats
Jeong Hun Shin, Young-Hyo Lim, Yi-Sun Song, Byung-Im So, Jun-Young Park, Cheng-Hu Fang, Yonggu Lee, Hyuck Kim, Kyung-Soo Kim
Diverse Regulation of Cardiac Expression of Relaxin Receptor by α1- and β1-Adrenoceptors
Xiao-Lei Moore, Yidan Su, Yingli Fan, You-Yi Zhang, Elizabeth A. Woodcock, Anthony M. Dart, Xiao-Jun Du
Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus
Robert S. Rosenson, Scott P. Rigby, Michael R. Jones, Hubert S. Chou
Galectin-3: A Modifiable Risk Factor in Heart Failure
Rudolf A. de Boer, A. Rogier van der Velde, Christian Mueller, Dirk J. van Veldhuisen, Stefan D. Anker, W. Frank Peacock, Kirkwood F. Adams, Alan Maisel
Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
A. Jalota, T. M. Scarabelli, L. Saravolatz, M. U. Bakhsh, P. Agrawal, R. Jalota, C. Chen-Scarabelli, V. Fuster, J. Halperin
Older Statin Initiators in Finland—Cardiovascular Risk Profiles and Persistence of Use
Eveliina Upmeier, Maarit Jaana Korhonen, Maria Rikala, Arja Helin-Salmivaara, Risto Huupponen
Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Throught The Femoral Approach. Rationale and Design
Carlo Briguori, Gabriella Visconti, Amelia Focaccio, Michael Donahue, Bruno Golia, Lucio Selvetella, Bruno Ricciarelli
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
John J. P. Kastelein, Jennifer G. Robinson, Michel Farnier, Michel Krempf, Gisle Langslet, Christelle Lorenzato, Daniel A. Gipe, Marie T. Baccara-Dinet